[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650462":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":30,"locations":29,"responsibleParty":36,"collaborators":29,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":29,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":29,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":64,"whyStopped":29,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":29},{"fullName":5,"class":6},"The First Affiliated Hospital of Anhui Medical University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"the continued RLRL treatment group(RLRL-C)","ACTIVE_COMPARATOR","The pediatric participants had received continuous Repeated low-level red light(RLRL) treatment for one year and continue to receive RLRL treatment for one more year.",[13],"Device: Repeated low-level red light (RLRL) therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"the discontinued RLRL treatment group (RLRL-I)","EXPERIMENTAL","The pediatric participants had received continuous Repeated low-level red light(RLRL) treatment for one year and discontinue RLRL treatment for one year.",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"the gradually reduced RLRL treatment group (RLRL-T)","The pediatric participants had received continuous Repeated low-level red light(RLRL) treatment for one year and gradually reduce the RLRL treatment for one year(First month: twice daily, for 5 days per week;Second month: Once daily, for 5 days per week;Third month: once daily, for 3 days per week).",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DEVICE","Repeated low-level red light (RLRL) therapy","Repeated low-level red light (RLRL) therapy is an emerging treatment modality for myopia control. The participants were randomly assigned to three groups: the continued RLRL treatment group (RLRL-C), the discontinued RLRL treatment group (RLRL-I), and the gradually reduced RLRL treatment group (RLRL-T).",[9,15,20],null,[31],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"Lixia Feng, Doctor","CONTACT","+8613075590585","lixiafeng75@fy.ahmu.edu.cn",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Lixia Feng","chief physician","100650462","the-rebound-effect-on-repeated-low-level-red-light-therapy-for-myopia-100650462",false,"NCT07748546","The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia","The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. 8 to 16 years old\n2. Rceived continuous RLRL treatment for 1 year (±1 month) without interruption.\n3. Diagnosed with myopia (ciliary muscle paralysis SER ≥ -0.50 D), astigmatism ≤ 2.50 D, anisometropia ≤ 1.50 D, and bilateral best corrected visual acuity (BCVA) ≥ Snellen 20\u002F20 before receiving RLRL treatment.\n4. The consent of the guardian and the consent of the participant.\n\nExclusion Criteria:\n\n1. History of any ophthalmic surgery or ocular diseases (e.g., glaucoma, retinal disorders).\n2. Systemic diseases that affect vision or eye health (e.g., diabetes). After discontinuing RLRL treatment, other myopia control interventions other than monocular glasses should be employed (including atropine, orthokeratology lenses, defocused\u002FDOT lenses, etc.).","ALL","8 Years","16 Years",{"count":51,"type":52},159,"ESTIMATED","INTERVENTIONAL",[55],"NA","Myopia is a global public health issue, projected to affect 49.8% of the world population by 2050, increasing risks of cataracts, glaucoma, macular degeneration, and retinal detachment. Repeated low-level red light (RLRL) therapy has shown promising myopia control in 12-month trials, reducing axial elongation by 69.4% and refractive progression by 76.6% versus spectacles, outperforming 0.01% atropine and benefiting orthokeratology poor responders. However, two-year data indicate declining efficacy in the second year and a rebound effect upon discontinuation, with progression rates matching untreated controls. This study enrolls participants who completed one year of continuous RLRL therapy to evaluate rebound effects on axial length and spherical equivalent refractive power among those who discontinue, gradually reduce, or continue treatment. Findings will inform strategies to optimize long-term RLRL protocols and mitigate post-treatment rebound.",[58,59],"Myopia","Randomized Controlled Trial (RCT)",[61,62,63],"myopia","randomized controlled trial","therapy","NOT_YET_RECRUITING","2026-08-02",{"date":67,"type":68},"2026-08-05","ACTUAL",{"date":70,"type":52},"2026-08-15",{"date":72,"type":52},"2028-07-15",{"name":5,"class":6}]